Cargando…
Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study
With the aim of describing the burden and epidemiology of community-acquired/healthcare-associated and hospital-acquired bloodstream infections (CA/HCA-BSIs and HA-BSIs) in patients hospitalised with COVID-19, and evaluating the risk factors for BSIs and their relative impact on mortality, an observ...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470708/ https://www.ncbi.nlm.nih.gov/pubmed/34572613 http://dx.doi.org/10.3390/antibiotics10091031 |
_version_ | 1784574269360963584 |
---|---|
author | Cona, Andrea Tavelli, Alessandro Renzelli, Andrea Varisco, Benedetta Bai, Francesca Tesoro, Daniele Za, Alessandro Biassoni, Caterina Battaglioli, Lodovica Allegrini, Marina Viganò, Ottavia Gazzola, Lidia Bini, Teresa Marchetti, Giulia Carla d’Arminio Monforte, Antonella |
author_facet | Cona, Andrea Tavelli, Alessandro Renzelli, Andrea Varisco, Benedetta Bai, Francesca Tesoro, Daniele Za, Alessandro Biassoni, Caterina Battaglioli, Lodovica Allegrini, Marina Viganò, Ottavia Gazzola, Lidia Bini, Teresa Marchetti, Giulia Carla d’Arminio Monforte, Antonella |
author_sort | Cona, Andrea |
collection | PubMed |
description | With the aim of describing the burden and epidemiology of community-acquired/healthcare-associated and hospital-acquired bloodstream infections (CA/HCA-BSIs and HA-BSIs) in patients hospitalised with COVID-19, and evaluating the risk factors for BSIs and their relative impact on mortality, an observational cohort study was performed on patients hospitalised with COVID-19 at San Paolo Hospital in Milan, Italy from 24 February to 30 November 2020. Among 1351 consecutive patients hospitalised with COVID-19, 18 (1.3%) had CA/HCA-BSI and 51 (3.8%) HA-BSI for a total of 82 episodes of BSI. The overall incidence of HA-BSI was 3.3/1000 patient-days (95% CI 2.4–4.2). Patients with HA-BSI had a longer hospital stay compared to CA/HCA-BSI and no-BSI groups (27 (IQR 21–35) vs. 12 (7–29) vs. 9 (5–17) median-days, p < 0.001) but a similar in-hospital mortality (31% vs. 33% vs. 25%, p = 0.421). BSI was not associated with an increased risk of mortality (CA/HCA-BSI vs. non-BSI aOR 1.27 95% CI 0.41–3.90, p = 0.681; HA-BSI vs. non-BSI aOR 1.29 95% CI 0.65–2.54, p = 0.463). Upon multivariate analysis, NIMV/CPAP (aOR 2.09, 95% CI 1.06–4.12, p = 0.034), IMV (aOR 5.13, 95% CI 2.08–12.65, p < 0.001) and corticosteroid treatment (aOR 2.11, 95% CI 1.06–4.19, p = 0.032) were confirmed as independent factors associated with HA-BSI. Development of HA-BSI did not significantly affect mortality. Patients treated with corticosteroid therapy had double the risk of developing BSI. |
format | Online Article Text |
id | pubmed-8470708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84707082021-09-27 Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study Cona, Andrea Tavelli, Alessandro Renzelli, Andrea Varisco, Benedetta Bai, Francesca Tesoro, Daniele Za, Alessandro Biassoni, Caterina Battaglioli, Lodovica Allegrini, Marina Viganò, Ottavia Gazzola, Lidia Bini, Teresa Marchetti, Giulia Carla d’Arminio Monforte, Antonella Antibiotics (Basel) Article With the aim of describing the burden and epidemiology of community-acquired/healthcare-associated and hospital-acquired bloodstream infections (CA/HCA-BSIs and HA-BSIs) in patients hospitalised with COVID-19, and evaluating the risk factors for BSIs and their relative impact on mortality, an observational cohort study was performed on patients hospitalised with COVID-19 at San Paolo Hospital in Milan, Italy from 24 February to 30 November 2020. Among 1351 consecutive patients hospitalised with COVID-19, 18 (1.3%) had CA/HCA-BSI and 51 (3.8%) HA-BSI for a total of 82 episodes of BSI. The overall incidence of HA-BSI was 3.3/1000 patient-days (95% CI 2.4–4.2). Patients with HA-BSI had a longer hospital stay compared to CA/HCA-BSI and no-BSI groups (27 (IQR 21–35) vs. 12 (7–29) vs. 9 (5–17) median-days, p < 0.001) but a similar in-hospital mortality (31% vs. 33% vs. 25%, p = 0.421). BSI was not associated with an increased risk of mortality (CA/HCA-BSI vs. non-BSI aOR 1.27 95% CI 0.41–3.90, p = 0.681; HA-BSI vs. non-BSI aOR 1.29 95% CI 0.65–2.54, p = 0.463). Upon multivariate analysis, NIMV/CPAP (aOR 2.09, 95% CI 1.06–4.12, p = 0.034), IMV (aOR 5.13, 95% CI 2.08–12.65, p < 0.001) and corticosteroid treatment (aOR 2.11, 95% CI 1.06–4.19, p = 0.032) were confirmed as independent factors associated with HA-BSI. Development of HA-BSI did not significantly affect mortality. Patients treated with corticosteroid therapy had double the risk of developing BSI. MDPI 2021-08-24 /pmc/articles/PMC8470708/ /pubmed/34572613 http://dx.doi.org/10.3390/antibiotics10091031 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cona, Andrea Tavelli, Alessandro Renzelli, Andrea Varisco, Benedetta Bai, Francesca Tesoro, Daniele Za, Alessandro Biassoni, Caterina Battaglioli, Lodovica Allegrini, Marina Viganò, Ottavia Gazzola, Lidia Bini, Teresa Marchetti, Giulia Carla d’Arminio Monforte, Antonella Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study |
title | Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study |
title_full | Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study |
title_fullStr | Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study |
title_full_unstemmed | Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study |
title_short | Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study |
title_sort | incidence, risk factors and impact on clinical outcomes of bloodstream infections in patients hospitalised with covid-19: a prospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470708/ https://www.ncbi.nlm.nih.gov/pubmed/34572613 http://dx.doi.org/10.3390/antibiotics10091031 |
work_keys_str_mv | AT conaandrea incidenceriskfactorsandimpactonclinicaloutcomesofbloodstreaminfectionsinpatientshospitalisedwithcovid19aprospectivecohortstudy AT tavellialessandro incidenceriskfactorsandimpactonclinicaloutcomesofbloodstreaminfectionsinpatientshospitalisedwithcovid19aprospectivecohortstudy AT renzelliandrea incidenceriskfactorsandimpactonclinicaloutcomesofbloodstreaminfectionsinpatientshospitalisedwithcovid19aprospectivecohortstudy AT variscobenedetta incidenceriskfactorsandimpactonclinicaloutcomesofbloodstreaminfectionsinpatientshospitalisedwithcovid19aprospectivecohortstudy AT baifrancesca incidenceriskfactorsandimpactonclinicaloutcomesofbloodstreaminfectionsinpatientshospitalisedwithcovid19aprospectivecohortstudy AT tesorodaniele incidenceriskfactorsandimpactonclinicaloutcomesofbloodstreaminfectionsinpatientshospitalisedwithcovid19aprospectivecohortstudy AT zaalessandro incidenceriskfactorsandimpactonclinicaloutcomesofbloodstreaminfectionsinpatientshospitalisedwithcovid19aprospectivecohortstudy AT biassonicaterina incidenceriskfactorsandimpactonclinicaloutcomesofbloodstreaminfectionsinpatientshospitalisedwithcovid19aprospectivecohortstudy AT battagliolilodovica incidenceriskfactorsandimpactonclinicaloutcomesofbloodstreaminfectionsinpatientshospitalisedwithcovid19aprospectivecohortstudy AT allegrinimarina incidenceriskfactorsandimpactonclinicaloutcomesofbloodstreaminfectionsinpatientshospitalisedwithcovid19aprospectivecohortstudy AT viganoottavia incidenceriskfactorsandimpactonclinicaloutcomesofbloodstreaminfectionsinpatientshospitalisedwithcovid19aprospectivecohortstudy AT gazzolalidia incidenceriskfactorsandimpactonclinicaloutcomesofbloodstreaminfectionsinpatientshospitalisedwithcovid19aprospectivecohortstudy AT biniteresa incidenceriskfactorsandimpactonclinicaloutcomesofbloodstreaminfectionsinpatientshospitalisedwithcovid19aprospectivecohortstudy AT marchettigiuliacarla incidenceriskfactorsandimpactonclinicaloutcomesofbloodstreaminfectionsinpatientshospitalisedwithcovid19aprospectivecohortstudy AT darminiomonforteantonella incidenceriskfactorsandimpactonclinicaloutcomesofbloodstreaminfectionsinpatientshospitalisedwithcovid19aprospectivecohortstudy |